TransThera Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
132
- Stock Symbol
-
02617
- Share Price
-
$0.97
- (As of Friday Closing)
TransThera General Information
Description
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Contact Information
Website
www.transthera.comCorporate Office
- 3rd Floor, Building 9, Phase II, Biomedical Valley Accelerator
- Jiangbei New Area
- Nanjing, Jiangsu 210032
- China
Corporate Office
- 3rd Floor, Building 9, Phase II, Biomedical Valley Accelerator
- Jiangbei New Area
- Nanjing, Jiangsu 210032
- China
TransThera Timeline
TransThera Stock Performance
As of 13-Nov-2026, TransThera’s stock price is $0.97. Its current market cap is $394M with 408M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.97 | $1.02 | $0.96 - $28.43 | $394M | 408M | 4.62M | -$0.10 |
TransThera Financials Summary
As of 30-Jun-2026, TransThera has a trailing 12-month revenue of $5.07M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 531,736 | 5,776,651 | ||
| Revenue | 5,067 | 0 | 0 | 167 |
| EBITDA | (39,024) | (41,122) | (37,648) | (49,175) |
| Net Income | (38,381) | (41,156) | (38,271) | (48,537) |
| Total Assets | 145,305 | 78,023 | 86,246 | 125,143 |
| Total Debt | 826 | 235 | 599 | 678 |
TransThera Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TransThera Comparisons
Industry
Financing
Details
TransThera Competitors (2)
One of TransThera’s 2 competitors is NovaBridge Biosciences, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NovaBridge Biosciences | Formerly VC-backed | Rockville, MD | ||||
| Ascentage Pharma | Formerly VC-backed | Suzhou, China |
TransThera Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TransThera Patents
TransThera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026194877-A1 | Pharmaceutical combination comprising bispecific antibody and multikinase inhibitor and use thereof | Pending | 17-Mar-2025 | ||
| WO-2026092344-A1 | Use of bruton's tyrosine kinase inhibitor | Pending | 28-Oct-2024 | ||
| WO-2026017098-A1 | Alox inhibitor and use thereof | Pending | 19-Jul-2024 | ||
| WO-2026017100-A1 | Alox inhibitor and use thereof | Pending | 19-Jul-2024 | ||
| AU-2024380002-A1 | Pharmaceutical composition and use thereof | Pending | 13-Nov-2023 | A61K31/551 |
TransThera Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TransThera ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
TransThera FAQs
-
When was TransThera founded?
TransThera was founded in 2014.
-
Where is TransThera headquartered?
TransThera is headquartered in Nanjing, China.
-
What is the size of TransThera?
TransThera has 132 total employees.
-
What industry is TransThera in?
TransThera’s primary industry is Drug Discovery.
-
Is TransThera a private or public company?
TransThera is a Public company.
-
What is TransThera’s stock symbol?
The ticker symbol for TransThera is 02617.
-
What is the current stock price of TransThera?
As of 13-Nov-2026 the stock price of TransThera is $0.97.
-
What is the current market cap of TransThera?
The current market capitalization of TransThera is $394M.
-
What is TransThera’s current revenue?
The trailing twelve month revenue for TransThera is $5.07M.
-
Who are TransThera’s competitors?
NovaBridge Biosciences and Ascentage Pharma are competitors of TransThera.
-
What is TransThera’s annual earnings per share (EPS)?
TransThera’s EPS for 12 months was -$0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
